



Clinical trial results:

A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2017-003220-78 |
| Trial protocol | DE |
| Global end of trial date | 14 November 2019 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 21 May 2020 |
| First version publication date | 21 May 2020 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | I8B-MC-ITSA |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|---------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03465878 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Trial Number: 16695 |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Eli Lilly and Company |
| Sponsor organisation address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Public contact | Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly, |
| Scientific contact | Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559, |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 14 November 2019 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 14 November 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus.

There are 2 parts to this study. Part A is investigating how the body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study treatment is given by subcutaneous injection. Part B of the study is investigating how the body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study treatment is given by continuous subcutaneous insulin infusion (CSII) pump.

Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 40 days in each part.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 26 March 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Canada: 53 |
| Country: Number of subjects enrolled | Germany: 28 |
| Worldwide total number of subjects | 81 |
| EEA total number of subjects | 28 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |

| | |
|---------------------------|----|
| Children (2-11 years) | 25 |
| Adolescents (12-17 years) | 27 |
| Adults (18-64 years) | 29 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants who completed Part A but discontinued before the beginning of Part B were replaced by newly enrolled participants in Part B.

Pre-assignment

Screening details:

No Text Available

Period 1

| | |
|------------------------------|-------------------------|
| Period 1 title | Period 1 |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Sequence 1-Part A |

Arm description:

Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog.

Period 1: LY900014

Period 2: Humalog

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.

| | |
|--|--------------------------|
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|------------------|-------------------|
| Arm title | Sequence 2-Part A |
|------------------|-------------------|

Arm description:

Participants received either single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014 or Humalog.

Period 1: Humalog

Period 2: LY900014

| | |
|--|--------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

| | |
|---|--------------------------|
| Dosage and administration details: | |
| Single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014. | |
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog. | |
| Arm title | Sequence 1-Part B |
| Arm description: | |
| Participants received either single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 or Humalog delivered using the CSII pump. | |
| Period 1: LY900014 | |
| Period 2: Humalog | |
| Arm type | Experimental |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Infusion |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump. | |
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Infusion |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump. | |
| Arm title | Sequence 2-Part B |
| Arm description: | |
| Participants received either single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 or Humalog with delivered using the CSII pump. | |
| Period 1: Humalog | |
| Period 2: LY900014 | |
| Arm type | Active comparator |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Infusion |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump. | |
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Infusion |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump. | |

| Number of subjects in period 1 | Sequence 1-Part A | Sequence 2-Part A | Sequence 1-Part B |
|--|-------------------|-------------------|-------------------|
| Started | 21 | 21 | 20 |
| Received at least 1 dose of study drug | 21 | 21 | 20 |
| Participants Moved From Part A to Part B | 0 ^[1] | 0 ^[2] | 15 ^[3] |
| Children (2-11 Years) | 7 ^[4] | 6 ^[5] | 6 ^[6] |
| Adolescents (12-17 Years) | 7 ^[7] | 7 ^[8] | 7 ^[9] |
| Adults (18-64 Years) | 7 ^[10] | 8 ^[11] | 7 ^[12] |
| Completed | 21 | 20 | 20 |
| Not completed | 0 | 1 | 0 |
| Consent withdrawn by subject | - | 1 | - |
| Physician decision | - | - | - |

| Number of subjects in period 1 | Sequence 2-Part B |
|--|--------------------|
| Started | 19 |
| Received at least 1 dose of study drug | 17 |
| Participants Moved From Part A to Part B | 10 ^[13] |
| Children (2-11 Years) | 6 ^[14] |
| Adolescents (12-17 Years) | 6 ^[15] |
| Adults (18-64 Years) | 7 ^[16] |
| Completed | 17 |
| Not completed | 2 |
| Consent withdrawn by subject | 1 |
| Physician decision | 1 |

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that

completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[9] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[10] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[11] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[12] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[13] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[14] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[15] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[16] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

Period 2

| | |
|------------------------------|-------------------------|
| Period 2 title | Period 2 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|---|--------------------------|
| Arm title | Sequence 1-Part A |
| Arm description: Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog. Period 1: LY900014 Period 2: Humalog | |
| Arm type | Experimental |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Single, subcutaneous (SC) dose of LY900014 administered via injection, in one of two study periods. | |
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Single, SC dose of insulin lispro (Humalog) administered via injection, in one of two study periods. | |
| Arm title | Sequence 2-Part A |
| Arm description: Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog. Period 1: Humalog Period 2: LY900014 | |
| Arm type | Experimental |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Single, subcutaneous (SC) dose of LY900014 administered via injection, in one of two study periods. | |
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Single, SC dose of insulin lispro (Humalog) administered via injection, in one of two study periods. | |
| Arm title | Sequence 1-Part B |
| Arm description: Participants received either single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 or Humalog delivered using the CSII pump. Period 1: LY900014 Period 2: Humalog | |
| Arm type | Experimental |

| | |
|--|--------------------|
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Single, subcutaneous (SC) dose of LY900014 administered via injection, in one of two study periods.

| | |
|--|--------------------------|
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Single, SC dose of insulin lispro (Humalog) administered via injection, in one of two study periods.

| | |
|------------------|-------------------|
| Arm title | Sequence 2-Part B |
|------------------|-------------------|

Arm description:

Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of 100 U/mL LY900014 or Humalog with delivered using the CSII pump.

Period 1: Humalog

Period 2: LY900014

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | LY900014 |
| Investigational medicinal product code | |
| Other name | Ultra-Rapid Lispro |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Single, subcutaneous (SC) dose of LY900014 administered via injection, in one of two study periods.

| | |
|--|--------------------------|
| Investigational medicinal product name | Humalog |
| Investigational medicinal product code | |
| Other name | Insulin Lispro; LY275585 |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Single, SC dose of insulin lispro (Humalog) administered via injection, in one of two study periods.

| Number of subjects in period 2 | Sequence 1-Part A | Sequence 2-Part A | Sequence 1-Part B |
|---------------------------------------|-------------------|-------------------|-------------------|
| Started | 21 | 20 | 20 |
| Children (2-11 Years) | 7 ^[17] | 6 ^[18] | 6 ^[19] |
| Adolescents (12-17 Years) | 7 ^[20] | 7 ^[21] | 7 ^[22] |
| Adults (18-64 Years) | 7 ^[23] | 7 ^[24] | 7 ^[25] |
| Completed | 21 | 20 | 20 |

| Number of subjects in period 2 | Sequence 2-Part B |
|---------------------------------------|-------------------|
| Started | 17 |
| Children (2-11 Years) | 6 ^[26] |

| | |
|---------------------------|--------|
| Adolescents (12-17 Years) | 6 [27] |
| Adults (18-64 Years) | 5 [28] |
| Completed | 17 |

Notes:

[17] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[18] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[19] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[20] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[21] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[22] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[23] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[24] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences.

[25] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[26] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[27] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

[28] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Milestones were added to show Age group differences and for the participants who moved from Part A to Part B.

Baseline characteristics

Reporting groups

| | |
|--------------------------------|----------|
| Reporting group title | Period 1 |
| Reporting group description: - | |

| Reporting group values | Period 1 | Total | |
|--|----------|-------|--|
| Number of subjects | 81 | 81 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 25 | 25 | |
| Adolescents (12-17 years) | 27 | 27 | |
| Adults (18-64 years) | 29 | 29 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 41 | 41 | |
| Male | 40 | 40 | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 2 | 2 | |
| Not Hispanic or Latino | 79 | 79 | |
| Unknown or Not Reported | 0 | 0 | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | |
| Asian | 4 | 4 | |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | |
| Black or African American | 1 | 1 | |
| White | 71 | 71 | |
| More than one race | 5 | 5 | |
| Unknown or Not Reported | 0 | 0 | |
| Region of Enrollment | | | |
| Units: Subjects | | | |
| Canada | 53 | 53 | |
| Germany | 28 | 28 | |

Subject analysis sets

| | |
|----------------------------|--------------|
| Subject analysis set title | Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014 or Humalog.

| | |
|----------------------------|--------------|
| Subject analysis set title | Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of either 100 U/mL LY900014 or Humalog delivered using the CSII pump.

| | |
|----------------------------|--------------------------|
| Subject analysis set title | Children-LY900014-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.

| | |
|----------------------------|-------------------------|
| Subject analysis set title | Children-Humalog-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Adolescents-LY900014-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.

| | |
|----------------------------|----------------------------|
| Subject analysis set title | Adolescents-Humalog-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|----------------------------|------------------------|
| Subject analysis set title | Adults-LY900014-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100U/mL LY900014.

| | |
|----------------------------|-----------------------|
| Subject analysis set title | Adults-Humalog-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|----------------------------|--------------------------|
| Subject analysis set title | Children-LY900014-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.

| | |
|----------------------------|-------------------------|
| Subject analysis set title | Children-Humalog-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Adolescents-LY900014-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.

| | |
|----------------------------|----------------------------|
| Subject analysis set title | Adolescents-Humalog-Part B |
|----------------------------|----------------------------|

| | |
|---|------------------------|
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump. | |
| Subject analysis set title | Adults-LY900014-Part B |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump. | |
| Subject analysis set title | Adults-Humalog-Part B |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump. | |

| Reporting group values | Part A | Part B | Children-LY900014-Part A |
|---|--------|--------|--------------------------|
| Number of subjects | 42 | 14 | 13 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Gender categorical Units: Subjects | | | |
| Female Male | | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino Not Hispanic or Latino Unknown or Not Reported | | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported | 0 | | |
| Region of Enrollment Units: Subjects | | | |

| | | | |
|---------|--|--|--|
| Canada | | | |
| Germany | | | |

| Reporting group values | Children-Humalog- Part A | Adolescents- LY900014-Part A | Adolescents- Humalog-Part A |
|---|-----------------------------|---------------------------------|--------------------------------|
| Number of subjects | 13 | 14 | 14 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Gender categorical Units: Subjects | | | |
| Female Male | | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino Not Hispanic or Latino Unknown or Not Reported | | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported | | | |
| Region of Enrollment Units: Subjects | | | |
| Canada Germany | | | |

| Reporting group values | Adults-LY900014- Part A | Adults-Humalog-Part A | Children-LY900014- Part B |
|---|----------------------------|--------------------------|------------------------------|
| Number of subjects | 14 | 14 | 11 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) | | | |

| | | | |
|---|--|--|--|
| Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Gender categorical Units: Subjects | | | |
| Female Male | | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino Not Hispanic or Latino Unknown or Not Reported | | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported | | | |
| Region of Enrollment Units: Subjects | | | |
| Canada Germany | | | |

| Reporting group values | Children-Humalog-Part B | Adolescents-LY900014-Part B | Adolescents-Humalog-Part B |
|---|-------------------------|-----------------------------|----------------------------|
| Number of subjects | 11 | 13 | 13 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Gender categorical Units: Subjects | | | |
| Female Male | | | |

| | | | |
|---|--|--|--|
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | | | |
| Not Hispanic or Latino | | | |
| Unknown or Not Reported | | | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | | | |
| Asian | | | |
| Native Hawaiian or Other Pacific Islander | | | |
| Black or African American | | | |
| White | | | |
| More than one race | | | |
| Unknown or Not Reported | | | |
| Region of Enrollment | | | |
| Units: Subjects | | | |
| Canada | | | |
| Germany | | | |

| | | | |
|--|------------------------|-----------------------|--|
| Reporting group values | Adults-LY900014-Part B | Adults-Humalog-Part B | |
| Number of subjects | 12 | 12 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | | | |
| Male | | | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | | | |
| Not Hispanic or Latino | | | |
| Unknown or Not Reported | | | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | | | |
| Asian | | | |
| Native Hawaiian or Other Pacific Islander | | | |
| Black or African American | | | |
| White | | | |

| | | | |
|---|--|--|--|
| More than one race Unknown or Not Reported | | | |
| Region of Enrollment Units: Subjects | | | |
| Canada Germany | | | |

End points

End points reporting groups

| | |
|---|-------------------|
| Reporting group title | Sequence 1-Part A |
| Reporting group description: Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog. Period 1: LY900014 Period 2: Humalog | |
| Reporting group title | Sequence 2-Part A |
| Reporting group description: Participants received either single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014 or Humalog. Period 1: Humalog Period 2: LY900014 | |
| Reporting group title | Sequence 1-Part B |
| Reporting group description: Participants received either single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 or Humalog delivered using the CSII pump. Period 1: LY900014 Period 2: Humalog | |
| Reporting group title | Sequence 2-Part B |
| Reporting group description: Participants received either single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 or Humalog with delivered using the CSII pump. Period 1: Humalog Period 2: LY900014 | |
| Reporting group title | Sequence 1-Part A |
| Reporting group description: Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog. Period 1: LY900014 Period 2: Humalog | |
| Reporting group title | Sequence 2-Part A |
| Reporting group description: Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog. Period 1: Humalog Period 2: LY900014 | |
| Reporting group title | Sequence 1-Part B |
| Reporting group description: Participants received either single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 or Humalog delivered using the CSII pump. Period 1: LY900014 Period 2: Humalog | |
| Reporting group title | Sequence 2-Part B |
| Reporting group description: Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of 100 U/mL LY900014 or Humalog with delivered using the CSII pump. Period 1: Humalog Period 2: LY900014 | |
| Subject analysis set title | Part A |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014 or Humalog. | |
| Subject analysis set title | Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of either 100 U/mL LY900014 or Humalog delivered using the CSII pump.

| | |
|----------------------------|--------------------------|
| Subject analysis set title | Children-LY900014-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.

| | |
|----------------------------|-------------------------|
| Subject analysis set title | Children-Humalog-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Adolescents-LY900014-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.

| | |
|----------------------------|----------------------------|
| Subject analysis set title | Adolescents-Humalog-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|----------------------------|------------------------|
| Subject analysis set title | Adults-LY900014-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100U/mL LY900014.

| | |
|----------------------------|-----------------------|
| Subject analysis set title | Adults-Humalog-Part A |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.

| | |
|----------------------------|--------------------------|
| Subject analysis set title | Children-LY900014-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.

| | |
|----------------------------|-------------------------|
| Subject analysis set title | Children-Humalog-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.

| | |
|----------------------------|-----------------------------|
| Subject analysis set title | Adolescents-LY900014-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.

| | |
|----------------------------|----------------------------|
| Subject analysis set title | Adolescents-Humalog-Part B |
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.

| | |
|----------------------------|------------------------|
| Subject analysis set title | Adults-LY900014-Part B |
|----------------------------|------------------------|

| | |
|---|---|
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump. | |
| Subject analysis set title | Adults-Humalog-Part B |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump. | |
| Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) following Each Treatment Arm for Each Study Part | |
| End point title | Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) following Each Treatment Arm for Each Study Part |
| End point description: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part. Analysis Population Description: All randomized participants who received at least one dose of study drug and had evaluable PK data. | |
| End point type | Primary |
| End point timeframe: Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes postdose | |

| End point values | Children- LY900014-Part A | Children- Humalog-Part A | Adolescents- LY900014-Part A | Adolescents- Humalog-Part A |
|---|---------------------------------|--------------------------------|------------------------------------|-----------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 13 | 13 | 14 | 14 |
| Units: picomols * hour per Liter | | | | |
| geometric mean (geometric coefficient of variation) | 755 (± 15) | 754 (± 17) | 962 (± 17) | 908 (± 21) |

| End point values | Adults- LY900014-Part A | Adults- Humalog-Part A | Children- LY900014-Part B | Children- Humalog-Part B |
|---|-------------------------------|------------------------------|---------------------------------|--------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 14 | 14 | 11 | 11 |
| Units: picomols * hour per Liter | | | | |
| geometric mean (geometric coefficient of variation) | 987 (± 20) | 975 (± 21) | 743 (± 17) | 714 (± 17) |

| End point values | Adolescents- LY900014-Part B | Adolescents- Humalog-Part B | Adults- LY900014-Part B | Adults- Humalog-Part B |
|------------------|------------------------------------|-----------------------------------|-------------------------------|------------------------------|
|------------------|------------------------------------|-----------------------------------|-------------------------------|------------------------------|

| | | | | |
|---|----------------------|----------------------|----------------------|----------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 13 | 13 | 11 | 12 |
| Units: picomols * hour per Liter | | | | |
| geometric mean (geometric coefficient of variation) | 842 (± 20) | 866 (± 16) | 1100 (± 35) | 1070 (± 35) |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | AUC(0 -7h) |
| Comparison groups | Children-LY900014-Part A v Children-Humalog-Part A |
| Number of subjects included in analysis | 26 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.9813 |
| Method | Mixed models analysis |
| Parameter estimate | Ratio of geometric least squares means |
| Point estimate | 0.999 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.918 |
| upper limit | 1.09 |

| | |
|---|--|
| Statistical analysis title | AUC(0 -7h) |
| Comparison groups | Adolescents-LY900014-Part A v Adolescents-Humalog-Part A |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.1638 |
| Method | Mixed models analysis |
| Parameter estimate | Ratio of geometric least squares means |
| Point estimate | 1.06 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.976 |
| upper limit | 1.15 |

| | |
|-----------------------------------|--|
| Statistical analysis title | AUC(0 -7h) |
| Comparison groups | Adults-LY900014-Part A v Adults-Humalog-Part A |

| | |
|---|--|
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.7623 |
| Method | Mixed models analysis |
| Parameter estimate | Ratio of geometric least squares means |
| Point estimate | 1.01 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.933 |
| upper limit | 1.1 |

| | |
|---|--|
| Statistical analysis title | AUC(0 -7h) |
| Comparison groups | Children-LY900014-Part B v Children-Humalog-Part B |
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.2952 |
| Method | Mixed models analysis |
| Parameter estimate | Ratio of geometric least squares means |
| Point estimate | 1.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.962 |
| upper limit | 1.13 |

| | |
|---|--|
| Statistical analysis title | AUC(0 -7h) |
| Comparison groups | Adolescents-LY900014-Part B v Adolescents-Humalog-Part B |
| Number of subjects included in analysis | 26 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.4052 |
| Method | Mixed models analysis |
| Parameter estimate | Ratio of geometric least squares means |
| Point estimate | 0.97 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.901 |
| upper limit | 1.04 |

| | |
|-----------------------------------|------------|
| Statistical analysis title | AUC(0 -7h) |
|-----------------------------------|------------|

| | |
|---|--|
| Comparison groups | Adults-LY900014-Part B v Adults-Humalog-Part B |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.5314 |
| Method | Mixed models analysis |
| Parameter estimate | Ratio of geometric least squares means |
| Point estimate | 1.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.948 |
| upper limit | 1.11 |

Secondary: Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part

| | |
|------------------------|--|
| End point title | Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part |
| End point description: | Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BGΔAUC(0-5h)) Following Each Treatment Arm for Each Study Part. Analysis Population Description: All randomized participants who received at least one dose of study drug and had evaluable Glucodynamics data. |
| End point type | Secondary |
| End point timeframe: | -30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240 and 300 minutes postdose |

| End point values | Children-LY900014-Part A | Children-Humalog-Part A | Adolescents-LY900014-Part A | Adolescents-Humalog-Part A |
|--|--------------------------|-------------------------|-----------------------------|----------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 12 | 12 | 13 | 13 |
| Units: milligrams * hour per deciliter | | | | |
| arithmetic mean (standard deviation) | 384 (± 335) | 492 (± 270) | 577 (± 247) | 651 (± 238) |

| End point values | Adults-LY900014-Part A | Adults-Humalog-Part A | Children-LY900014-Part B | Children-Humalog-Part B |
|--|------------------------|-----------------------|--------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 14 | 14 | 10 | 10 |
| Units: milligrams * hour per deciliter | | | | |
| arithmetic mean (standard deviation) | 372 (± 179) | 351 (± 240) | 602 (± 221) | 582 (± 254) |

| End point values | Adolescents- LY900014-Part B | Adolescents- Humalog-Part B | Adults- LY900014-Part B | Adults- Humalog-Part B |
|--|------------------------------------|-----------------------------------|-------------------------------|------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 13 | 13 | 12 | 12 |
| Units: milligrams * hour per deciliter | | | | |
| arithmetic mean (standard deviation) | 614 (± 160) | 614 (± 163) | 343 (± 194) | 401 (± 235) |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

I8B-MC-ITSA

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 21.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------------------|
| Reporting group title | Children-LY900014-Part A |
|-----------------------|--------------------------|

Reporting group description: -

| | |
|-----------------------|-------------------------|
| Reporting group title | Children-Humalog-Part A |
|-----------------------|-------------------------|

Reporting group description: -

| | |
|-----------------------|-----------------------------|
| Reporting group title | Adolescents-LY900014-Part A |
|-----------------------|-----------------------------|

Reporting group description: -

| | |
|-----------------------|----------------------------|
| Reporting group title | Adolescents-Humalog-Part A |
|-----------------------|----------------------------|

Reporting group description: -

| | |
|-----------------------|------------------------|
| Reporting group title | Adults-LY900014-Part A |
|-----------------------|------------------------|

Reporting group description: -

| | |
|-----------------------|-----------------------|
| Reporting group title | Adults-Humalog-Part A |
|-----------------------|-----------------------|

Reporting group description: -

| | |
|-----------------------|--------------------------|
| Reporting group title | Children-LY900014-Part B |
|-----------------------|--------------------------|

Reporting group description: -

| | |
|-----------------------|-------------------------|
| Reporting group title | Children-Humalog-Part B |
|-----------------------|-------------------------|

Reporting group description: -

| | |
|-----------------------|-----------------------------|
| Reporting group title | Adolescents-LY900014-Part B |
|-----------------------|-----------------------------|

Reporting group description: -

| | |
|-----------------------|----------------------------|
| Reporting group title | Adolescents-Humalog-Part B |
|-----------------------|----------------------------|

Reporting group description: -

| | |
|-----------------------|------------------------|
| Reporting group title | Adults-LY900014-Part B |
|-----------------------|------------------------|

Reporting group description: -

| | |
|-----------------------|-----------------------|
| Reporting group title | Adults-Humalog-Part B |
|-----------------------|-----------------------|

Reporting group description: -

| Serious adverse events | Children-LY900014-Part A | Children-Humalog-Part A | Adolescents-LY900014-Part A |
|---|--------------------------|-------------------------|-----------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 1 / 14 (7.14%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| injury | | | |
| alternative dictionary used: | | | |

| | | | |
|---|----------------|----------------|----------------|
| MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Adolescents-Humalog-Part A | Adults-LY900014-Part A | Adults-Humalog-Part A |
|---|----------------------------|------------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 14 (0.00%) | 0 / 15 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| injury | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 14 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Children-LY900014-Part B | Children-Humalog-Part B | Adolescents-LY900014-Part B |
|---|--------------------------|-------------------------|-----------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 13 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| injury | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Adolescents-Humalog-Part B | Adults-LY900014-Part B | Adults-Humalog-Part B |
|---|----------------------------|------------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--|----------------|----------------|----------------|
| injury | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Children-LY900014- Part A | Children-Humalog- Part A | Adolescents- LY900014-Part A |
|--|------------------------------|-----------------------------|---------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 4 / 13 (30.77%) | 4 / 13 (30.77%) | 6 / 14 (42.86%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| lipoma | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 13 (7.69%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| feeling hot | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| injection site discomfort | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| injection site erythema | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 13 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 2 | 0 | 2 |
| injection site pain | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 13 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| injection site pruritus | | | |

| | | | |
|--|--|--|--|
| alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Immune system disorders seasonal allergy alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Reproductive system and breast disorders dysmenorrhoea alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) ovarian cyst ruptured alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 0 / 14 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders epistaxis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Injury, poisoning and procedural complications procedural pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Nervous system disorders dizziness alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) headache alternative dictionary used: MedDRA 21.1 | 0 / 13 (0.00%) 0 0 | 0 / 13 (0.00%) 0 0 | 0 / 14 (0.00%) 0 0 |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| nausea | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 13 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| vomiting | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| lipohypertrophy | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 13 (7.69%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 1 | 1 |
| Renal and urinary disorders | | | |
| leukocyturia | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 13 (7.69%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Endocrine disorders | | | |
| hypothyroidism | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 21.1 | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 13 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |

| | | | |
|---|---------------------|----------------------|---------------------|
| acne pustular alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| cystitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| ear infection alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| gastroenteritis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| groin abscess alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| nasopharyngitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 2 / 13 (15.38%) 2 | 1 / 14 (7.14%) 1 |
| upper respiratory tract infection alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Metabolism and nutrition disorders hyperglycaemia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 1 / 13 (7.69%) 1 | 0 / 14 (0.00%) 0 |

| | | | |
|-----------------------------------|----------------------------|------------------------|-----------------------|
| Non-serious adverse events | Adolescents-Humalog-Part A | Adults-LY900014-Part A | Adults-Humalog-Part A |
|-----------------------------------|----------------------------|------------------------|-----------------------|

| | | | |
|--|---------------------|---------------------|---------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 3 / 14 (21.43%) | 2 / 14 (14.29%) | 2 / 15 (13.33%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) lipoma alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| General disorders and administration site conditions feeling hot alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| injection site discomfort alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| injection site erythema alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 1 / 14 (7.14%) 1 | 0 / 15 (0.00%) 0 |
| injection site pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| injection site pruritus alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Immune system disorders seasonal allergy alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| dysmenorrhoea alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| ovarian cyst ruptured alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Respiratory, thoracic and mediastinal disorders epistaxis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Injury, poisoning and procedural complications procedural pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Nervous system disorders dizziness alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| headache alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Gastrointestinal disorders abdominal pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| nausea alternative dictionary used: MedDRA 21.1 | | | |

| | | | |
|---|--|--|--|
| subjects affected / exposed occurrences (all) vomiting alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 1 / 14 (7.14%) 1 | 1 / 14 (7.14%) 1 1 / 14 (7.14%) 1 | 0 / 15 (0.00%) 0 0 / 15 (0.00%) 0 |
| Skin and subcutaneous tissue disorders lipohypertrophy alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Renal and urinary disorders leukocyturia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Endocrine disorders hypothyroidism alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Infections and infestations acne pustular alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) cystitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) ear infection | 0 / 14 (0.00%) 0 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 0 / 15 (0.00%) 0 |

| | | | |
|---|---------------------|---------------------|---------------------|
| alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| gastroenteritis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| groin abscess alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| nasopharyngitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| upper respiratory tract infection alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Metabolism and nutrition disorders hyperglycaemia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 15 (0.00%) 0 |

| Non-serious adverse events | Children-LY900014- Part B | Children-Humalog- Part B | Adolescents- LY900014-Part B |
|---|------------------------------|-----------------------------|---------------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 6 / 12 (50.00%) | 4 / 12 (33.33%) | 3 / 13 (23.08%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) lipoma alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| General disorders and administration site conditions | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| feeling hot alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| injection site discomfort alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 13 (7.69%) 1 |
| injection site erythema alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| injection site pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 1 / 13 (7.69%) 1 |
| injection site pruritus alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Immune system disorders seasonal allergy alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Reproductive system and breast disorders dysmenorrhoea alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| ovarian cyst ruptured alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Respiratory, thoracic and mediastinal | | | |

| | | | |
|---|---|---|---|
| disorders epistaxis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 |
| Injury, poisoning and procedural complications procedural pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Nervous system disorders dizziness alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) headache alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 |
| Gastrointestinal disorders abdominal pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) nausea alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) vomiting alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 |
| Skin and subcutaneous tissue disorders lipohypertrophy alternative dictionary used: MedDRA 21.1 | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 1 / 13 (7.69%) 1 |
| Renal and urinary disorders leukocyturia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Endocrine disorders hypothyroidism alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Infections and infestations acne pustular alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| cystitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| ear infection alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| gastroenteritis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 |
| groin abscess | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| nasopharyngitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| upper respiratory tract infection alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 |
| Metabolism and nutrition disorders hyperglycaemia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 1 / 12 (8.33%) 1 | 0 / 13 (0.00%) 0 |

| Non-serious adverse events | Adolescents- Humalog-Part B | Adults-LY900014- Part B | Adults-Humalog-Part B |
|---|--------------------------------|----------------------------|--------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 1 / 13 (7.69%) | 3 / 12 (25.00%) | 2 / 12 (16.67%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) lipoma alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| General disorders and administration site conditions feeling hot alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| injection site discomfort alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| injection site erythema | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| injection site pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 | 1 / 12 (8.33%) 1 |
| injection site pruritus alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Immune system disorders seasonal allergy alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Reproductive system and breast disorders dysmenorrhoea alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| ovarian cyst ruptured alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders epistaxis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Injury, poisoning and procedural complications procedural pain alternative dictionary used: MedDRA 21.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Nervous system disorders dizziness alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) headache alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 |
| Gastrointestinal disorders abdominal pain alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) nausea alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) vomiting alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 0 / 12 (0.00%) 0 |
| Skin and subcutaneous tissue disorders lipohypertrophy alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Renal and urinary disorders leukocyturia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Endocrine disorders | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| hypothyroidism alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Infections and infestations acne pustular alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| cystitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| ear infection alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| gastroenteritis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| groin abscess alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| nasopharyngitis alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| upper respiratory tract infection | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Metabolism and nutrition disorders hyperglycaemia alternative dictionary used: MedDRA 21.1 subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|---|
| 19 March 2018 | Protocol (b): Total daily insulin dose was updated in inclusion criteria. |
| 17 April 2018 | Protocol (c): Inpatient Procedures for Part A and B was updated. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported